Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty

A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 (Vocacapsaicin) in Subjects Undergoing Total Knee Arthroplasty

This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.

Study Overview

• Status: Completed
• Conditions: Postsurgical Pain
• Intervention / Treatment: Drug: Placebo; Drug: CA-008

Detailed Description

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study evaluating, in a pilot stage of the study, up to 3 ascending dose level cohorts each evaluating a single dose of CA-008 vs. placebo injected/instilled during an elective TKA. Up to 54 subjects will be randomized in the pilot stage. During the optional second stage of the study, subjects will be randomized to one of either 2 or 3 CA-008 dose levels (to be determined) or placebo. The Sponsor made the decision not to proceed with the second stage.

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77402
      • HD Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Plan to undergo an elective primary unilateral total knee arthroplasty (TKA or knee replacement), without collateral procedure or additional surgeries.
2. Be a reasonably healthy adult aged 18 - 80 years old, inclusive, with a BMI ≤ 36 kg/m2 and American Society of Anesthesiology (ASA) physical Class 1, 2 or 3 at the time of randomization.
3. Males and females must abstain from intercourse, use acceptable birth control methods or be sterile or otherwise incapable of having children.
4. Be willing and able to sign the informed consent form (ICF)
5. Be willing and able to complete study procedures and pain scales and to communicate meaningfully in English. Be able and willing to return for outpatient follow up visits as required.

Key Exclusion Criteria:

1. In the opinion of the Investigator,

   1. have a concurrent painful condition, other than pain in the knee to be replaced, that may require pain treatment during the study period.
   2. have active skin disease or other clinically significant abnormality at the anticipated site of surgery that could interfere with the planned surgery.
2. Have a known allergy to chili peppers, capsaicin or the components of CA-008, ropivacaine, ketorolac, acetaminophen, fentanyl, hydromorphone, morphine or oxycodone.
3. Have significant medical, neuropsychiatric or other condition.

4. The following are considered disallowed medications:

   1. tolerant to opioids as defined
   2. capsaicin-containing products or foods.
   3. central nervous system active agent as an analgesic adjunct medication
   4. antiarrhythmics except beta-blockers, digoxin, warfarin, lithium, or aminoglycosides or other antibiotics for an infection
   5. parenteral or oral corticosteroids.
   6. antianginal, antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days or which is not expected to remain stable while participating in the study.
5. Have positive results on the alcohol breath/saliva test indicative of alcohol abuse or urine drug screen indicative of illicit drug use at screening, and/or prior to surgery.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: CA-008 5 mg (0.05 mg/mL) Cohort 1; Cohort 1 (5 mg), was prepared at 0.05 mg/mL CA-008 (vocacapsaicin)	Drug: CA-008; 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL); Other Names: vocacapsaicin
Placebo Comparator: Placebo - Cohort 1; Placebo for Cohort 1 Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active	Drug: Placebo; Placebo
Active Comparator: CA-008 10 mg (0.1 mg/mL) Cohort 2; Cohort 2 (10 mg), was prepared at 0.1 mg/mL CA-008 (vocacapsaicin)	Drug: CA-008; 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL); Other Names: vocacapsaicin
Active Comparator: CA-008 15 mg (0.15 mg/mL) Cohort 3; Cohort 3 (15 mg), was prepared at 0.15 mg/mL CA-008 (vocacapsaicin)	Drug: CA-008; 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL); Other Names: vocacapsaicin
Placebo Comparator: Placebo - Cohorts 2 and 3; Placebo - Cohorts 2 and 3 Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active	Drug: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time-specific Mean Pain Intensity Scores (NRS) at Time 96 Hours for CA-008 vs. Placebo	Primary Efficacy Endpoint for the Pilot Stage. Time-specific mean pain intensity scores at Time 96 hours for CA-008 vs. placebo based on a 10-point numerical rating scale (NRS) from 0-10 where 0 is no pain and 10 is the worst pain imaginable).	At 96 hours
CA-008 Dose vs. Placebo Comparison: Area Under the Curve (AUC) 0 to 96 Hours	Primary Efficacy Endpoint for Stage 2. Area Under the Curve (AUC) of the NRS current pain intensity scores from Time 0 hours to 96 hours at rest (AUC0 to 96h) where 0 is no pain and 10 is the worst pain imaginable for CA-008 compared to placebo. • During the inpatient stay, NRS at rest beginning with the PACU admission may be assessed once the subject is awake. The maximum is an NRS score of 10 x all 96 hours = 960 NRS units*hrs; the minimum is 0 x 96h = 0 NRS units*hrs	From 0 hours to 96 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Who do Not Require Opioids	Key Secondary Efficacy Endpoints for Stage 2. For each CA-008 dose vs. placebo comparison, percentage of subjects who do not require opioids.	Time 0 hours to Time 96 hours: Opioid Free 0 hours to 96 hours
Total Opioid Consumption (in Daily Oral Morphine Equivalents)	Key Secondary Efficacy Endpoints for Stage 2. Mean total postoperative opioid consumption (in daily oral morphine equivalents) for CA-008 compared to placebo	OC from Time 0 hours to Time 96 hours: OC 0 hours to 96 hours

Collaborators and Investigators

• Sponsor: Concentric Analgesics
• Investigators: Principal Investigator: Daneshvari Solanki, MD, First Surgical Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 29, 2018
• Primary Completion (Actual): April 30, 2019
• Study Completion (Actual): May 31, 2019

Study Registration Dates

• First Submitted: October 24, 2018
• First Submitted That Met QC Criteria: November 5, 2018
• First Posted (Actual): November 6, 2018

Study Record Updates

• Last Update Posted (Actual): February 15, 2022
• Last Update Submitted That Met QC Criteria: January 25, 2022
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative
• Other Study ID Numbers: CA-PS-203

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No